Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

CKD-MBD: impact on management of kidney disease

CKD-MBD: impact on management of kidney disease Chronic kidney disease (CKD) causes various bone mineral disorders, which have recently been named CKD mineral and bone disorder (CKD-MBD). CKD-MBD is associated with extremely high cardiovascular disease (CVD) morbidity and mortality in the endstage kidney disease (ESKD) population. Thus, optimal management of CKD-MBD would lead to a reduction in cardiovascular morbidity and mortality in uremic patients. In addition, it has been suggested that the treatment of CKD-MBD has some favorable effects on the progression of CKD. Recently, novel therapeutic agents, including active vitamin D analogues, noncalcium-containing phosphate binders, and cinacalcet, have become clinically available. In this article, we review novel therapeutic strategies for CKD-MBD. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical and Experimental Nephrology Springer Journals

Loading next page...
 
/lp/springer-journals/ckd-mbd-impact-on-management-of-kidney-disease-TaYu8YUZP3

References (95)

Publisher
Springer Journals
Copyright
Copyright © 2007 by Japanese Society of Nephrology
Subject
Medicine & Public Health; Nephrology; Urology
ISSN
1342-1751
eISSN
1437-7799
DOI
10.1007/s10157-007-0492-5
pmid
18085385
Publisher site
See Article on Publisher Site

Abstract

Chronic kidney disease (CKD) causes various bone mineral disorders, which have recently been named CKD mineral and bone disorder (CKD-MBD). CKD-MBD is associated with extremely high cardiovascular disease (CVD) morbidity and mortality in the endstage kidney disease (ESKD) population. Thus, optimal management of CKD-MBD would lead to a reduction in cardiovascular morbidity and mortality in uremic patients. In addition, it has been suggested that the treatment of CKD-MBD has some favorable effects on the progression of CKD. Recently, novel therapeutic agents, including active vitamin D analogues, noncalcium-containing phosphate binders, and cinacalcet, have become clinically available. In this article, we review novel therapeutic strategies for CKD-MBD.

Journal

Clinical and Experimental NephrologySpringer Journals

Published: Dec 1, 2007

There are no references for this article.